Zentalis Pharmaceuticals

ZNTL

Market cap $190M

2.94 USD

-0.31

9.54%

At close Updated Jan 23, 4:00 PM EST

Pre-market

After hours

2.94

0.00

1 day

-9.54%

5 days

-6.96%

1 month

117.78%

3 months

79.27%

6 months

94.7%

Year to date

114.6%

1 year

27.83%

5 years

-93.29%

10 years

-87.33%

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 166

Healthcare Biotechnology